2021-12-12
Cornell dots, originally developed 16 years ago in the lab of Uli Wiesner, the Spencer T. Olin Professor of Engineering, have just begun their third human clinical trial. The newest iteration, C’dot drug conjugates, is being developed by Elucida Oncology as a treatment for patients with advanced, recurrent or refractory cancers overexpressing folate-receptor alpha (FRα), including ovarian,...